Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Bial Drug Tragedy: French Senate To Look Afresh At Clinical Trial Rules

This article was originally published in SRA

Executive Summary

A French Senate committee has intervened in the debate over the Phase I study of a new drug that caused the death of one volunteer and led to the hospitalization of several others, saying that it plans to meet with the government inspectors who visited the site in Rennes to discuss their findings, with a view to looking afresh at the legislation governing clinical trials1.

Advertisement
Advertisement
UsernamePublicRestriction

Register

PS118520

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel